Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to examine the healthcare costs among patients with CML receiving dasatinib or nilotinib as first line therapy in a commercially or Medicare insured population.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CML subjects receiving Dasatinib | CML receiving dasatinib as first or second line therapy will be conducted to assess healthcare costs | ||
| CML subjects receiving Nilotinib | CML receiving nilotinib as first or second line therapy will be conducted to assess healthcare costs |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Healthcare costs | Average (mean) costs for patients receiving dasatinib or nilotinib as first line therapy | Intent-to-treat (ITT) at 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Healthcare costs by line of therapy | Intent-to-treat (ITT) at 6 months | |
| Resource utilization by line of therapy | Captured per number of hospitalizations, Emergency room (ER) visits, physician office visits, and medications / number of prescriptions |
Not provided
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Others: Retrospecitve database analysis of patients in a health plan
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Franklin Pharmaceutical Consulting, Llc | Clinton | South Carolina | 29325 | United States |
Not provided
| ID | Term |
|---|---|
| D015464 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
| ID | Term |
|---|---|
| D007951 | Leukemia, Myeloid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| Intent-to-treat (ITT) at 6 months |
| D009196 |
| Myeloproliferative Disorders |
| D001855 | Bone Marrow Diseases |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |